Difficult to obtain antibody drugs are now available as research consumables
Cyramza® The reference Ramucirumab Drug
Divided into tubes
Ramucirumab Drug Aliquots
Aliquots of the reference drug Ramucirumab are now available as research consumables.
Ramucirumab drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Ramucirumab drug can be ordered at the same time. Several other reference drugs are also available.
The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug. Are you thinking why buy aliquots?
What our clients say
“Evidentic’s Drug aliquots helped us to ascertain the efficacy of our novel molecule [in comparison to commercial therapeutic antibody] which supported our fundraising efforts. ”
Evidentic drug aliquots have helped us speed up our antibody characterization assays and selection of clonal cell lines. An easy and reliable source!
”Evidentic can supply different batches of reference products for precilinical research.The quick access to the on-stock batches allows for adhoc ordering, keeps costs down and makes a headstart possible!”
“Evidentic is a new source of cost-efficient therapeutic mAbs for our immonassays. And easy to order!”
“We develop innovative and biosimilar mAbs for a global market. Evidentic’s aRMPs are a great source of cost-efficient reference products for our research and development program.”
“Evidentic was the only source that offered small aliquots of original therapeutic mAbs at an affordable price range. The aliquots came in an easy-to-use-and-store format that was apt for my research purpose.”
Ramucirumab / Cyramza
|API type||Ramucirumab is a human IgG1 monoclonal antibody produced in murine (NS0) cells by recombinant DNA technology.|
|Pharmacotherapeutic group||Antineoplastic agents, monoclonal antibodies|
|Target of antibody||VEGFR2; Synonyms: CD309, FLK1, VEGFR, 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR-2, sVEGFR2, Vegfr-2, FLK-1, flk-1, vegfr-2, KDR, FLK/KDR, flk1, flk1b, kdrb, si:busm1-205d10.1, si:ch211-254j6.1, si:ch211-278f21.4, wu:fc31a09|
(Mechanism of action; Source EMA document)
|Vascular Endothelial Growth Factor (VEGF) Receptor 2 is the key mediator of VEGF induced|
angiogenesis. Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF
Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits
ligand stimulated activation of VEGF Receptor 2 and its downstream signalling components,
including p44/p42 mitogen-activated protein kinases, neutralising ligand-induced proliferation and
migration of human endothelial cells.
|Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)|
|Original license holder|
|Marketing authorisation numbers||EU/1/14/957/001 - 003|
|Marketing authorisation holder||Eli Lilly Nederland B.V.|
3528 BJ Utrecht
|Name of the manufacturer of the biological active substance||ImClone Systems LLC|
33 ImClone Drive,
Eli Lilly S.A.
|Name and address of the manufacturer(s) responsible for batch release||Lilly, S.A.|
Avda de la Industria, 30
|Max shelf life||36 months|
|Storage conditions||2°C – 8°C|
|List of excipients||Histidine|
Polysorbate 80 (E433)
Water for injections